EE589 Cost-Effectiveness of Once-Daily Somatropin From Sandoz Versus Once-Weekly Somatrogon for the Treatment of Growth Hormone Deficiency in Children and Adolescents

Recent approval of once-weekly somatrogon for Growth Hormone Deficiency (GHD) treatment in paediatric patients has provided an opportunity to assess its economic impact compared to already available once-daily somatropin. This research aims to determine the cost-effectiveness of weekly somatrogon compared to daily somatropin from Sandoz for the treatment of paediatric GHD, from the perspective of payers in Germany and the United Kingdom (UK).
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research